Physiological release of striatal acetylcholine (in vivo): Effect of somatostatin on dopaminergic-cholinergic interaction

Brain Research Bulletin

Volumn 61, Issue 5, 2003, Pages 529-536

  Rakovska, Angelina ^a   Javitt, Daniel ^b,c   Raichev, Peter ^a   Ang, Rosalind ^b   Balla, Andrea ^b   Aspromonte, John ^b   Vizi, Sylvester ^d  

^a INSTITUTE OF PHYSIOLOGY   (Bulgaria)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Acetylcholine release; DA release; Microdialysis; Somatostatin; Striatum

Indexed keywords

ACETYLCHOLINE; APOMORPHINE; BROMOCRIPTINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; OXIDOPAMINE; SOMATOSTATIN; SULPIRIDE; TETRODOTOXIN;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL INTERACTION; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG POTENTIATION; ELECTROCHEMICAL ANALYSIS; EXTRACELLULAR SPACE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HORMONE INHIBITION; MALE; MICRODIALYSIS; MOLECULAR PROBE; NERVE POTENTIAL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT; STRIATONIGRAL DEGENERATION;

EID: 0141455277     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00192-8     Document Type: Article

References (49)

1. Arneric S.P., Reis D.J. Somatostatin and cholecystokinin octapeptide differentially modulate the release of [3H] acetylcholine from caudate nucleus but not cerebral cortex: role of dopamine receptor activation. Brain Res. 374:1986;153-161.
2. Aronin N., Cooper A., Lorenz L.J., Bird E.D., Sagar S.M., Leeman S.E., Martin J.B. Somatostatin is increased in the basal ganglia in Huntington's disease. Ann. Neurol. 13:1983;519-526.
3. Badger T.M., Sagar S.M., Millard W.J., Martin J.B., Rosenblum P. Cysteamine reduces serum gonadotropin concentrations in adult male rats. Life Sci. 30:1982;245-252.
4. Beal M.F., Martin J.B. Effects of neuropeptide drugs on brain somatostatin-like immunoreactivity. Neurosci. Lett. 47:1984;125-130.
5. 2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J. Neurochem. 54:1990;2145-2148.
6. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., River J., Guilemin R. Hypothalamic polypeptide that inhibits secretion on immunoreactive pituitary growth hormone. Science. 179:1973;77-79.
7. Chesselet M., Reisine T. Somatostatin regulates dopaminergic release in striatal slices and cat caudate nuclei. J. Neurosci. 3:1983;232-236.
8. Damsma G., DeBoer P., Westerink B.H.C., Fibiger H.C. Dopaminergic regulation of striatal cholinergic interneurons: an in vivo microdialysis study. Naunyn-Schmiedeberg Arch. Pharmacol. 342:1990;523-527.
9. Damsma G., Lammerts V., Bueren D., Westerink B.H.C., Horn A.S. Determination of acetylcholine in the femtomole range by means of HPLC, a post-column enzyme reactor, and electro-chemical detection. Chromatographia. 24:1987;827-831.
10. 2 dopamine receptor subtypes. JPET. 277:1996;775-783.
11. DeBoer P., Abercrombie E.D., Heeringa M., Westerink B.H.C. Differential effect of systemic administration of bromcriptine and L-DOPA on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats. Brain Res. 608:1993;198-203.
12. Epelbaum J. Somatostatin in the central nervous system: physiological and pathological modifications. Prog. Neurobiol. 27:1986;63-100.
13. Gerner R.H., Yamada T. Altered neuropeptide concentration in cerebrospinal fluid of psychiatric patients. Brain Res. 238:1982;298-302.
14. Giovannini M.G., Mutolo D., Bianchi L., Michelassi A., Pepeu G. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study. J. Neurosci. 14:1994;1358-1365.
15. Guyenet P.G., Agid Y., Javoy F., Beaujouan J.C., Rossier J., Glowinsky J. Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system. Brain Res. 84:1975;227-244.
16. Hathway G., Emson P., Humphrey P., Kendrick K. Somatostatin potently stimulates in vivo striatal dopamine and γ-aminobutyric acid release by a glutamate-dependent action. J. Neurochem. 70(4):1998;1740-1749.
17. Hendry H.C., Jones E.G., Emson R.C. Morphology distribution and synaptic relations of somatostatin- and neuropeptide Y-immunoreactive neurons in rat and monkey cortex. J. Neurosci. 4:1984;2497-2517.
18. Johansson O., Hokfelt T., Elde R.P. Immunochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience. 13:1984;265-339.
19. Kawaguchi J., Wilson C.J., Augood S.J., Emson P.S. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
20. Ladinsky H., Consolo S., Bianchi S., Smanin R., Ghezzi D. Cholinergic-dopaminergic interaction in the striatum: the effect of 6-hydroxydopamine or pimozide treatment on the increased striatal acetylcholine levels induced by apomorphine, piribedil and D-amphetamine. Brain Res. 84:1975;221-226.
21. Lewis D.A., Hayres T.L., Lund J.S., Oeth K.M. Dopamine and the neural circuitry of primate prefrontal cortex: implications for schizophrenia research. Neuropsychopharmacology. 6:1992;127-134.
22. Molchan S.E., Lawlor B.A., Hill J.L., Martinez R.A., Davis C.L., Mellow A.M., Rubinow D.R., Sunderland T. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol. Psychiatry. 29:1991;1110-1118.
23. Pallis E., Thermos T., Spyraki Ch. Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. Eur. J. Neurosci. 14:2001;763-767.
24. G. Paxinos, G. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1982.
25. Prosperini E., Rizzi M., Fumagalli F., Tarrizo G., Samanin R., Bendotti C. Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms. J. Neurochem. 69:1997;206-213.
26. Radke J.M., McLennan A.J., Vincent S.R., Fibiger H.C. Comparison between short- and long-term haloperidol administration or somatostatin and substance P concentrations in the rat brain. Brain Res. 480:1989;178-183.
27. Radke J.M., Spyraki C., Thermos K. Neuronal release of somatostatin in the rat striatum: an in vivo microdialysis study. Neuroscience. 54(2):1993;493-498.
28. Rakovska A., Kiss J.P., Raichev P., Lazarova M., Kalfin R., Milenov K. Somatostatin stimulates striatal acetylcholine release by glutamatergic receptors: an in vivo microdialysis study. Neurochem. Int. 40(3):2002;269-275.
29. Rakovska A.D., Kiss J.P., Raichev P., Lazarova M., Kalfin R., Djambazova E. The non-competitive AMPA receptor antagonist (GYKI 52466) blocks quisqualate-induced acetylcholine release from the rat hippocampus and striatum: an in vivo microdialysis study. Neurochem. Int. 40:2002;419-426.
30. A.D. Rakovska, P. Raichev, M. Lazarova, R. Kalfin, J.P. Kiss, E.S. Vizi, Effect of somatostatin on dopaminergic-cholinergic interaction in the striatum: an in vivo microdialysis study in freely moving rats. IBRO Workshop, Debrecen, Hungary, 24-27 January 2002.
31. Robertson G.S., Tham C.S., Wilson C., Jakubovic A., Fibiger H.C. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J. Pharmacol. Exp. Ther. 264:1993;1344-1351.
32. O.P. Rostad, L.C. Terry, J.B. Martin, Somatostatin and nervous system, in: J.L. Barker, T.G. Smith, Jr. (Eds.), The role of Peptides in Neuronal Function, Dekker, New York, 1980, p. 573.
33. Rubinow D.R. Cerebrospinal fluid, somatostatin and psychiatric illness. Biol. Psychol. 21:1986;341-365.
34. Schindler M., Humphrey P.P.A., Emson P.C. Somatostatin receptors in the central nervous system. Prog. Neurobiol. 50:1996;17-20.
35. Schindler M., Sellers L., Humphrey P., Emson P. Immunohistochemical localization of the somatostatin SST2 (A) receptor in the rat brain and spinal cord. Neuroscience. 76:1999;225-240.
36. Smiley J.F., McGinnis J.P., Javitt D. Nitric oxide synthase interneurons in the monkey cerebral cortex are subsets of the somatostatin, neuropetide Y, and calbindin cells. Brain Res. 863:2000;205-212.
37. Stoof J.C., Drukarch B., DeBoer P., Westerink B.H.C., Groenewegen H.J. Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience. 47:1992;755-770.
38. Takahashi H., Shintani Y., Okauchi T., Ishikawa M., Bando H., Azekawa T., Morita Y., Saito S. Measurement of somatostatin release in rat brain by microdialysis. J. Neurosci. Methods. 52:1994;33-38.
39. D. Tarsy, Dopamine-acetylcholine interaction in the basal ganglia, in: W.S. Stratton Fields (Ed.), Neurotransmitter Function: Basic and Clinical Aspects, Raven Press, New York, 1977, pp. 213-246.
40. Tatsuoka Y., Riskind P.N., Beal M.F., Martin J.B. The effect of amphetamine on the in vivo release of dopamine, somatostatin, and neuropeptide Y form rat caudate nucleus. Brain Res. 411:1987;200-203.
41. Thermos K., Radke J., Kastellakis A., Anagnostakis Y., Spyraki C. Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study. Synapse. 22:1996;209-216.
42. Vincent S., Johanson O. Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: a light and electronic microscopic study. J. Comp. Neurol. 217:1983;264-270.
43. Vincent S.R., Staines W.A., Fibiger H.C. Histochemical demonstration of separate populations of somatostatin and cholinergic neurons in the rat striatum. Neurosci. Lett. 35:1983;111-114.
44. E.S. Vizi, Non-Synaptic Interaction between Neurons, Wiley, Chichester, 1985.
45. E.S. Vizi, Non-synaptic inhibitory signal transmission between axon terminals: physiological and pharmacological evidence, in: K. Fuxe, L.F. Agnati (Eds.), Advances in Neuroscience. Volume Transmission in the Brain: Novel Mechanisms for Neural Transmission, Raven Press, New York, 1991, pp. 89-96.
46. Vizi E.S. Role of high-affinity receptors and membrane transporters in non-synaptic communication and drug action in the CNS. Pharmacol. Rev. 52:2000;63-89.
47. 5 enkephalinamide. Neuroscience. 2:1977;953-961.
48. Vuillet J., Kerkerion L., Kachidian P., Boster O., Nieullon A. Ultrastructural correlates of functional relationships between nigral dopaminergic or cortical afferents fibers and neuropeptide-Y-containing neurons in the rat striatum. Neurosci. Lett. 100:1989;99-104.
49. Vizi E.S., Labos E. Non-synaptic interactions at presynaptic level. Prog. Neurobiol. 37:1991;145-163.